Market Currents

• Sunday, November 22, 2009

• 00:00 AM Barron's Bill Alpert thinks investors are overestimating the potential of Valeant Pharmaceuticals' (VRX) prospective epilepsy drug (retigabine) to offset waning royalties from its top-selling antiviral drug ribavirin. Two key issues are widespread complaints of side effects by test subjects, and a fierce push by prescription-drug plans to move patients to generics. Comment!

• Tuesday, August 4, 2009

• 08:23 AM Valeant Pharmaceuticals International (VRX): Q2 EPS of $0.51 beats by $0.07. Revenue of $192M (+25%) vs. $181M. Shares +5.6% premarket. (PR) Comment!
• 00:05 AM Notable earnings before Tuesday's open: ADM, ARM, AYE, CAM, CBB, CTSH, CVS, DHI, DISCA, DNR, DUK, EMR, ETR, EXPD, FTR, HCP, HNT, ICE, ICON, JOE, LPX, MAC, NI, PGN, PNW, PPL, RDC, SE, SPG, THC, TRW, UPL, VNO, VRX, WTI Comment!

• Tuesday, June 16, 2009

• 10:38 AM Sometimes simple remedies end up curing complex diseases. And sometimes it's the opposite: A pre-cancer cream manufactured by Valeant Pharmaceuticals (VRX +2.4%) also smooths wrinkles and erases brown spots. Comment!

• Tuesday, May 5, 2009

• 09:00 AM Premarket gainers: ACAD +24%. MGM 16%. LVS +13%. XTXI +12%. AIG +11%. THC +10%. TKLC +9%. GERN +9%. EGLE +8%. ALKS +7%. FIG +6%. DRYS +6%. VRX +6%. AMLN +6%. YGE +6%. KFT +5%. CENX +5%. CTSH +5%. PCX +6%. CSIQ +5%. BZH +5%. NM +4%. EXM +4%. CDE +4%.
  Losers: BZ -21%. HOLX -20%. HLIT -15%. MYGN -14%. LM -11%. NMM -10%. PQ -10%. AXA -9%. PNX -8%. HEP -8%. ADM -7%. CHK -6%. DHI -5%. FITB -4%. RDN -5%. AKS -4%. AIB -4%. UL -4%. IRE -4%. KFN -4%. Comment!
• 08:15 AM Valeant Pharmaceuticals (VRX): Q1 EPS of $0.46 beats by $0.23. Revenue of $178M (+17%) vs. $175M. Shares +5.6% premarket. (PR) Comment!
• 00:05 AM Notable earnings before Tuesday's open: ADM, ADP, ALU, AVP, AYE, BAM, CBB, CEG, CTSH, CVS, DNR, DRH, DUK, EMR, FCL, FE, HEW, HNT, ICE, JOE, KFT, LM, LPX, MAC, MVL, PAG, PCP, PGN, PNW, PQ, RDN, SE, SRE, TAP, TEVA, UNT, VRX, VTR, WEC, WTI, WY, WYNN, XEC
    Comment!

• Tuesday, February 24, 2009

• 08:27 AM Valeant Pharmaceuticals International (VRX): Q4 EPS of $0.52 beats by $0.24. Revenue of $183M (-3.1%) vs. $185M. (PR) Comment!
• 00:05 AM Notable earnings before Tuesday's open: FE, FWLT, GTI, HD, HNZ, M, MGA, MHS, ODP, PCG, PKD, PWR, RDN, RSH, SRE, TGT, THC, VPHM, VRX Comment!

• Thursday, November 6, 2008

• 00:05 AM Notable earnings before Thursday's open: ABH, ABV, AN, ANSS, ARD, BRL, BX, BZH, CCOI, CDL, CEG, CHTR, CLR, CXW, DPTR, DTV, DYN, EP, FLO, FTO, GOL, HK, HUN, IAG, INCY, JRCC, KG, LAMR, LINE, NDAQ, NRF, OMG, OMX, PCG, PNK, PRGO, SE, SFY, SNH, SONS, TEL, TEVA, TM, VCI, VRX, WEN, WMB, WNR, WRC Comment!

• Thursday, August 28, 2008

• 11:09 AM GlaxoSmithKline (GSK) signs a deal worth up to $820M with Valeant Pharmaceuticals (VRX) for access to the firm's experimental epilepsy treatments. Glaxo has made several deals with smaller partners to expand its pipeline of experimental medicines . Comment!

• Monday, August 11, 2008

• 00:05 AM Notable earnings before Monday's open: CNO, HYGS, LINTA, PEIX, RDN, RTK, SYY, VRX Comment!